A significant partnership announcement today may inject fresh upward momentum into the innovative drug sector. A leading Hong Kong-listed pharmaceutical company disclosed that its subsidiary has entered a strategic collaboration with AstraZeneca PLC (AZN). The partnership will focus on conducting clinical trials for a novel targeted-immunotherapy combination in non-small cell lung cancer, once again drawing market attention to domestic innovative drug companies.
The trading activity for the market's only ETF tracking the Hang Seng Innovation Drug Index, the HUATAI BAIRUI HANG SENG INNOVATION DRUG TRADING OPEN ENDED INDEX SECURITIES INVESTMENT FUND (QDII) (520500), remains exceptionally high. The product's daily turnover has surpassed 10 billion yuan for nine consecutive trading days, reaching 2.764 billion yuan this Monday, marking its highest level since April 3 this year. With a current fund size of 2.448 billion yuan, its on-market liquidity performance is notably strong.
Movements by industrial capital also convey positive signals, with a sustained wave of share buybacks and stake increases within the pharmaceutical sector this year. Since June alone, over 20 pharmaceutical companies have disclosed or initiated share purchase or buyback plans. This flurry of activity underscores the confidence industry players have in the sector's long-term growth prospects. Internationally, private equity firm KKR, in partnership with Sixth Street Partners, recently finalized a $1 billion preferred stock financing deal to support biotech firm BridgeBio Pharma in developing new drugs for genetic diseases. This reflects growing recognition of the long-term value in the global innovative drug space by international capital.
Analyzing the Sector's Fundamentals
From an industrial logic perspective, the innovative drug sector is experiencing a confluence of three cyclical tailwinds. First, amid an aging population trend, healthcare demand exhibits a rigid and continuously growing characteristic. Second, the international expansion of domestically developed innovative drugs is accelerating. The total value of Chinese innovative drug out-licensing deals reached $135.655 billion in 2025. In the first quarter of 2026 alone, the figure exceeded $60 billion, approaching half of last year's total. Third, payment-side reforms are progressing steadily. A dual-support system combining basic medical insurance and commercial health insurance is gradually taking shape. Pathways for high-end new drugs to be included in commercial insurance and linked to basic insurance are becoming smoother. Many regions are lifting restrictions on the number of drugs hospitals can use, gradually clearing key bottlenecks for the clinical adoption and market penetration of innovative drugs.
Analyst Perspective on Valuation
Northeast Securities points out that the window for a value re-rating of core leading Hong Kong-listed innovative drug companies has arrived, with ample room for upward valuation adjustment. Currently, the broader Hong Kong-listed innovative drug sector is at a historically low valuation level, potentially opening a comprehensive window for value re-assessment. Priority should be given to leading pharmaceutical companies with mature commercial revenue streams, robust pipelines, and ownership of first-in-class/best-in-class differentiated cutting-edge assets, as they possess substantial room for upward revaluation.
ETF Profile and Strategy
It is reported that the Hang Seng Innovation Drug Index, which the HUATAI BAIRUI HANG SENG INNOVATION DRUG TRADING OPEN ENDED INDEX SECURITIES INVESTMENT FUND (QDII) (520500) closely tracks, invests in 40 leading Hong Kong-listed innovative drug companies through the QDII mechanism. It primarily focuses on mid-to-upstream innovative drug fields such as biopharmaceuticals, chemical drugs, and active pharmaceutical ingredients, assembling a group of R&D-driven enterprises with strong development capabilities and potential. This ETF features a relatively large size and superior liquidity, and supports intraday T+0 trading. Against the backdrop of potential business development deal realizations, profit inflection points, and policy support, it may serve as a convenient tool for gaining exposure to opportunities in the Hong Kong-listed innovative drug sector.
About the Fund Manager
The manager of the HUATAI BAIRUI HANG SENG INNOVATION DRUG TRADING OPEN ENDED INDEX SECURITIES INVESTMENT FUND (QDII) (520500), Huatai-PineBridge Fund Management, is one of China's first ETF managers. With over 19 years of experience in the index investment field, it has created transparent, convenient, and low-cost index tools for investors, such as the Huatai-PineBridge CSI 300 ETF (510300) and the Huatai-PineBridge A500 ETF (563360). As of the end of March 2026, the company's ETFs had cumulatively generated profits exceeding 223.4 billion yuan for its holders over the past two years, making it one of only three public fund management companies in the A-share market to achieve cumulative profits exceeding 200 billion yuan during the same period.